Company intelligence / Profile preview
Xeno Biosciences
Cambridge, Massachusetts, United Statesxenobiosciences.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
Xeno Biosciences developed XEN‑101, an oral small molecule designed to induce weight loss by shifting the gut microbiome to a state similar to that seen after gastric bypass surgery. The drug showed high tolerability and safety in early clinical trials but did not demonstrate sufficient efficacy for weight loss. In early 2025, LPOXY Therapeutics acquired key assets from Xeno, including clinical data and IP, to repurpose the compound as SIDIPREV™ for prevention of C. difficile infection in hospitalized patients.[6]
- Therapeutic areas
- EndocrinologyMetabolic Disorders
- Modalities
- Small molecules (oral, gut-restricted compounds)[1][3][5]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Xeno Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xeno Biosciences.